ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

NMRA Neumora Therapeutics Inc

9.99
0.00 (0.00%)
Pre Mercado
Última actualización: 03:05:15
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Neumora Therapeutics Inc NMRA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 9.99 03:05:15
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
9.99
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/5/202406:00GLOBENeumora Therapeutics Announces Initiation of Phase 2 Study..
07/5/202415:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202406:15EDGAR2Form 8-K - Current report
07/5/202406:00GLOBENeumora Therapeutics Reports First Quarter 2024 Financial..
06/5/202406:00GLOBENeumora Therapeutics to Participate in Upcoming Conferences..
15/4/202405:30GLOBENeumora Therapeutics Announces Clinical Hold of Phase 1..
13/3/202406:00GLOBENeumora Therapeutics to Participate at Stifel 2024 Virtual..
07/3/202415:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/3/202406:08EDGAR2Form 8-K - Current report
07/3/202406:00GLOBENeumora Therapeutics Reports Fourth Quarter and Full Year..
16/2/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202406:00GLOBENeumora Therapeutics Appoints Kaya Pai Panandiker as Chief..
08/1/202407:32EDGAR2Form 8-K - Current report
02/1/202406:00GLOBENeumora Therapeutics to Present at 42nd Annual J.P. Morgan..
15/12/202316:06EDGAR2Form SC 13D/A - General statement of acquisition of..
12/12/202306:00GLOBENeumora Therapeutics Appoints Jason Duncan as Chief Legal..
28/11/202315:21EDGAR2Form 8-K - Current report
27/11/202306:00GLOBENeumora Therapeutics Announces NMRA-266 IND Clearance and..
01/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202315:01EDGAR2Form 8-K - Current report
01/11/202306:00GLOBENeumora Therapeutics Reports Third Quarter 2023 Financial..
30/10/202306:00GLOBENeumora Therapeutics to Participate in Upcoming Conferences..
10/10/202306:00GLOBENeumora Therapeutics Announces Appointment of Robert Lenz,..
14/9/202319:49GLOBENeumora Therapeutics Announces Pricing of Initial Public..